Sort   by:  
 Page size 
UnknownBrexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.
Not available
S-EPMC11532701 | biostudies-literature
UnknownClinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.
Not available
S-EPMC12485315 | biostudies-literature
UnknownEthnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX.
Not available
S-EPMC10719464 | biostudies-literature
UnknownSociospatial structure explains marked variation in brucellosis seroprevalence in an Alpine ibex population.
Not available
S-EPMC5688143 | biostudies-literature
UnknownBCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia.
Not available
S-EPMC11874845 | biostudies-literature
UnknownRNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma.
Not available
S-EPMC8541503 | biostudies-literature
UnknownCD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.
Not available
S-EPMC12283004 | biostudies-literature
UnknownEZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.
Not available
S-EPMC10457196 | biostudies-literature
UnknownCombined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.
Not available
S-EPMC10730928 | biostudies-literature
UnknownObinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenstrom macroglobulinemia.
Not available
S-EPMC8114554 | biostudies-literature
Sort   by:  
 Page size